These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 4742496)
1. Delayed toxicity of 4'-demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) (NSC-122819; VM-26) in mice. Avery TL; Roberts D; Price RA Cancer Chemother Rep; 1973 Apr; 57(2):165-73. PubMed ID: 4742496 [No Abstract] [Full Text] [Related]
2. Response of L1210 leukemia to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea plus 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-beta-D-glucopyranoside). Roberts D; Peck C; Hilliard S; Karas JG Cancer Res; 1981 Oct; 41(10):3891-5. PubMed ID: 7284998 [No Abstract] [Full Text] [Related]
3. Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213). Nissen NI; Larsen V; Pedersen H; Thomsen K Cancer Chemother Rep; 1972 Dec; 56(6):769-77. PubMed ID: 4634038 [No Abstract] [Full Text] [Related]
4. Acute, chronic and terminal toxicity to 4'-demethylepipodophyllotoxin thenylidene glucoside (VM26) in mice. Hacker M; Roberts DW Cancer Res; 1975 Jul; 35(7):1756-60. PubMed ID: 1131830 [TBL] [Abstract][Full Text] [Related]
5. Sedimentation of DNA from L1210 cells after treatment with 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) or 1-beta-D-arabinofuranosylcytosine or both drugs. Roberts D; Hilliard S; Peck C Cancer Res; 1980 Nov; 40(11):4225-31. PubMed ID: 7471063 [No Abstract] [Full Text] [Related]
6. 4'-demethylepipodophyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside) (NSC-122819; VM-26) and 4'-demethylepipodophyllotoxin 9-(4.6-0-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213) in childhood cancer: preliminary observations. Rivera G; Avery T; Pratt C Cancer Chemother Rep; 1975; 59(4):743-9. PubMed ID: 1100225 [TBL] [Abstract][Full Text] [Related]
7. Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia. Dombernowsky P; Nissen NI Acta Pathol Microbiol Scand A; 1973 Sep; 81(5):715-24. PubMed ID: 4771975 [No Abstract] [Full Text] [Related]
8. Combination chemotherapy with cytosine arabinoside, L-asparaginase, and 6-azauridine for transplantable murine leukemias. Avery TL; Roberts D Cancer Res; 1973 Apr; 33(4):791-9. PubMed ID: 4696479 [No Abstract] [Full Text] [Related]
9. Effect of reserpine (NSC-59272)-induced hypothermia on lifespan in mouse L1210 leukemia. Fondy TP; Karker KL; Calcagnino C; Emlich CA Cancer Chemother Rep; 1974; 58(3):317-24. PubMed ID: 4841715 [No Abstract] [Full Text] [Related]
10. Delayed toxicity of epipodophyllotoxin derivatives (VM 26 and VP 16-213), due to a local effect. Stähelin H Eur J Cancer (1965); 1976 Nov; 12(11):925-31. PubMed ID: 991901 [No Abstract] [Full Text] [Related]
11. Protection with N-acetyl-L-cysteine (NSC-111180) against isophosphamide (NSC-109724) toxicity and enhancement of therapeutic effect in early murine L1210 leukemia. Kline I; Gang M; Woodman RJ; Cysyk RL; Venditti JM Cancer Chemother Rep; 1973; 57(3):299-304. PubMed ID: 4751256 [No Abstract] [Full Text] [Related]
12. Comparative cytotoxic and cytokinetic effects of the epipodophyllotoxins 4'-demethylepipodophyllotoxin-9-(4,6-O-2-ethylidene-beta-D-glucopyranoside) and 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) and their metabolites on human leukemic lymphoblasts. Dow LW; Sinkule JA; Look AT; Horvath A; Evans WE Cancer Res; 1983 Dec; 43(12 Pt 1):5699-706. PubMed ID: 6580063 [TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy with 4'Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia. Dombernowsky P; Nissen NI Eur J Cancer (1965); 1976 Mar; 12(3):181-8. PubMed ID: 939236 [No Abstract] [Full Text] [Related]
14. Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors. Stähelin H Eur J Cancer (1965); 1973 Mar; 9(3):215-21. PubMed ID: 4787856 [No Abstract] [Full Text] [Related]
15. Antileukemic synergism between cyclophosphamide and an antitumor platinum compound. Walker EM; Gale GR Res Commun Chem Pathol Pharmacol; 1973 Sep; 6(2):419-25. PubMed ID: 4750093 [No Abstract] [Full Text] [Related]
16. Modification of transplantability and tumor growth following treatment of L1210 leukemia and TA3Ha cells with macromomycin (NSC-170105). Lippman MM; Abbott BJ Cancer Chemother Rep; 1973; 57(4):501-3. PubMed ID: 4762442 [No Abstract] [Full Text] [Related]
17. Effect of different doses of methotrexate (NSC-740), cytosine arabinoside (NSC-63878), and cyclophosphamide (NSC-26271) on drug resistance in mice with L1210 leukemia. Schmid FA; Hutchison DJ Cancer Chemother Rep; 1972 Aug; 56(4):473-81. PubMed ID: 5081590 [No Abstract] [Full Text] [Related]
18. Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213. Rivera G; Avery T; Roberts DW Eur J Cancer (1965); 1975 Sep; 11(9):639-47. PubMed ID: 1220978 [No Abstract] [Full Text] [Related]
19. Uridine enhances the chemotherapeutic action of the 4'-demethylepipodophyllotoxin-thenylidene-glucoside (VM 26)-cyclophosphamide combination on i.m. implanted Ehrlich carcinoma. Osswald H Arzneimittelforschung; 1978; 28(3):387-8. PubMed ID: 580745 [TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of the antispermatogenic agent, 2,3-dihydro-2-(1-naphthyl)-4(1H)-quinazolinone (NSC-145669). Neil GL; Li LH; Buskirk HH; Moxley TE Cancer Chemother Rep; 1972 Apr; 56(2):163-73. PubMed ID: 5043224 [No Abstract] [Full Text] [Related] [Next] [New Search]